WO2000037025A3 - Antibodies to truncated vegf-d and uses thereof - Google Patents

Antibodies to truncated vegf-d and uses thereof Download PDF

Info

Publication number
WO2000037025A3
WO2000037025A3 PCT/US1999/031332 US9931332W WO0037025A3 WO 2000037025 A3 WO2000037025 A3 WO 2000037025A3 US 9931332 W US9931332 W US 9931332W WO 0037025 A3 WO0037025 A3 WO 0037025A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
antibodies
vegfr
interfere
truncated vegf
Prior art date
Application number
PCT/US1999/031332
Other languages
French (fr)
Other versions
WO2000037025A2 (en
Inventor
Marc G Achen
Steven Alan Stacker
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to CA002355896A priority Critical patent/CA2355896A1/en
Priority to KR1020017007826A priority patent/KR20010081089A/en
Priority to DE69930872T priority patent/DE69930872T8/en
Priority to AU33432/00A priority patent/AU770332B2/en
Priority to EP99969995A priority patent/EP1140175B1/en
Priority to JP2000589139A priority patent/JP4632543B2/en
Publication of WO2000037025A2 publication Critical patent/WO2000037025A2/en
Publication of WO2000037025A3 publication Critical patent/WO2000037025A3/en
Priority to HK01107909A priority patent/HK1038687A1/en
Priority to AU2004202080A priority patent/AU2004202080A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
PCT/US1999/031332 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof WO2000037025A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002355896A CA2355896A1 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof
KR1020017007826A KR20010081089A (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof
DE69930872T DE69930872T8 (en) 1998-12-21 1999-12-21 ANTIBODIES AGAINST SHORTENED VEGF-D AND ITS USES
AU33432/00A AU770332B2 (en) 1998-12-21 1999-12-21 Antibodies to truncated VEGF-D and uses thereof
EP99969995A EP1140175B1 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof
JP2000589139A JP4632543B2 (en) 1998-12-21 1999-12-21 Cleaved VEGF-D antibody and use thereof
HK01107909A HK1038687A1 (en) 1998-12-21 2001-11-09 Antibodies to truncated vegf-d and uses thereof
AU2004202080A AU2004202080A1 (en) 1998-12-21 2004-05-17 Antibodies to truncated VEGF-D and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11325498P 1998-12-21 1998-12-21
US60/113,254 1998-12-21
US13455699P 1999-05-17 1999-05-17
US60/134,556 1999-05-17

Publications (2)

Publication Number Publication Date
WO2000037025A2 WO2000037025A2 (en) 2000-06-29
WO2000037025A3 true WO2000037025A3 (en) 2000-11-16

Family

ID=26810852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/031332 WO2000037025A2 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof

Country Status (13)

Country Link
US (3) US6383484B1 (en)
EP (1) EP1140175B1 (en)
JP (1) JP4632543B2 (en)
KR (1) KR20010081089A (en)
CN (1) CN1330555A (en)
AT (1) ATE322909T1 (en)
AU (2) AU770332B2 (en)
CA (1) CA2355896A1 (en)
DE (1) DE69930872T8 (en)
DK (1) DK1140175T3 (en)
ES (1) ES2259247T3 (en)
PT (1) PT1140175E (en)
WO (1) WO2000037025A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
ES2341864T3 (en) * 1995-09-29 2010-06-29 Universita Degli Studi Di Siena REGULATED GENES AND USES OF THE SAME.
ATE306546T1 (en) 1996-08-23 2005-10-15 Ludwig Inst Cancer Res RECOMBINANT VASCULAR ENDOTHELIAL CELL GROWTH FACTOR D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
EP1248642A4 (en) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Vegf-d/vegf-c/vegf peptidomimetic inhibitor
AU3988401A (en) * 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
CA2401665A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
JP2004511430A (en) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド Bispecific immunoglobulin-like antigen binding protein and production method
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002244055A1 (en) * 2001-02-12 2002-08-28 The Penn State Research Foundation Fra-1 expression in brain cancer
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
DE60236646D1 (en) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 antibodies
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN100497389C (en) 2001-06-13 2009-06-10 根马布股份公司 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2452058A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2003006104A2 (en) * 2001-07-12 2003-01-23 Ludwig Institute For Cancer Research Lymphatic endothelial cells materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
EP1545588A4 (en) * 2002-07-23 2007-12-05 Ludwig Inst Cancer Res Methods and compositions for activating or inhibiting vegf-d and vegf-c
US7465547B2 (en) * 2002-11-12 2008-12-16 Mochida Pharmaceutical Co., Ltd. Methods for detecting human low molecular weight CD14
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
DE10256410B3 (en) * 2002-12-02 2004-03-11 Daimlerchrysler Ag Energy management method for automobile air-conditioning device, has air-conditioning compressors controlled in dependence on assigned priorities upon detection of defined engine operating conditions
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
EP1594527A2 (en) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells
EP1635860A2 (en) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
CN102813923B (en) 2003-08-27 2015-04-01 奥普索特克公司 Combination therapy for the treatment of ocular neovascular disorders
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
ES2350269T3 (en) * 2006-01-18 2011-01-20 The General Hospital Corporation METHODS TO INCREASE LYMPHATIC FUNCTION.
US7667880B2 (en) * 2006-02-10 2010-02-23 Adobe Systems, Incorporated Method and apparatus for previewing digital motion picture content
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
AR066660A1 (en) * 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
DE102007038730A1 (en) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Evidence of Human Vascular Endothelial Growth Factor
CN101245106B (en) * 2007-12-04 2011-07-20 澳赛尔斯生物技术（上海）有限公司 Anti-VRGF acceptor monoclone antibody, preparation method and application thereof
US7811776B2 (en) * 2007-12-05 2010-10-12 University Of Cincinnati Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
EP2294184A4 (en) 2008-06-30 2013-03-06 Mesoblast Inc Treatment of eye diseases and excessive neovascularization using a combined therapy
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
EP2393832B1 (en) * 2009-02-06 2015-07-08 Pepscan Systems BV Truncated cystine-knot proteins
LT3912643T (en) 2009-02-13 2023-02-10 Immunomedics Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2427496A4 (en) * 2009-04-03 2013-05-15 Vegenics Pty Ltd Anti-vegf-d antibodies
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CN103501825B (en) 2011-05-02 2017-03-15 免疫医疗公司 The ultrafiltration concentration of the antibody selected for the allotype that small size is applied
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN107753954A (en) 2012-12-13 2018-03-06 免疫医疗公司 The dosage of the antibody that effect is improved and toxicity reduces and SN 38 immunoconjugates
DK2956476T3 (en) 2013-02-18 2020-02-17 Vegenics Pty Ltd LANDAND-BINDING MOLECULES AND APPLICATIONS THEREOF
KR20220061248A (en) 2013-07-12 2022-05-12 이베릭 바이오, 인크. Methods for treating or preventing ophthalmological conditions
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (en) 2014-02-25 2016-10-12 免疫医疗公司 Humanized RFB4 anti-CD22 antibody
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (en) 2014-10-07 2023-12-01 免疫医疗公司 New adjuvant use of antibody-drug conjugates
CN107428837A (en) 2015-04-22 2017-12-01 免疫医疗公司 Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2
SI3313443T1 (en) 2015-06-25 2023-11-30 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
SI3316885T1 (en) 2015-07-01 2021-09-30 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN108794629A (en) * 2018-06-28 2018-11-13 浙江众意生物科技有限公司 A kind of VEGF-D monoclonal antibodies and kit
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
JP3911028B2 (en) * 1996-07-15 2007-05-09 中外製薬株式会社 Novel VEGF-like factor
EP1054687B8 (en) * 1997-12-24 2008-07-16 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor

Also Published As

Publication number Publication date
CN1330555A (en) 2002-01-09
KR20010081089A (en) 2001-08-25
DE69930872T2 (en) 2006-11-30
WO2000037025A2 (en) 2000-06-29
JP2002532113A (en) 2002-10-02
ATE322909T1 (en) 2006-04-15
US7097986B2 (en) 2006-08-29
AU2004202080A1 (en) 2004-06-10
EP1140175B1 (en) 2006-04-12
US20040141917A1 (en) 2004-07-22
EP1140175A4 (en) 2003-03-05
AU3343200A (en) 2000-07-12
US6730489B1 (en) 2004-05-04
EP1140175A2 (en) 2001-10-10
AU770332B2 (en) 2004-02-19
JP4632543B2 (en) 2011-02-16
US6383484B1 (en) 2002-05-07
PT1140175E (en) 2006-06-30
DE69930872T8 (en) 2007-05-03
CA2355896A1 (en) 2000-06-29
DE69930872D1 (en) 2006-05-24
DK1140175T3 (en) 2006-08-14
ES2259247T3 (en) 2006-09-16

Similar Documents

Publication Publication Date Title
WO2000037025A3 (en) Antibodies to truncated vegf-d and uses thereof
DE69841273D1 (en) METHOD FOR IDENTIFYING BINDING DOMAINS THAT KEEP THEIR EPITOPHINENESS ABILITY
BR8606615A (en) COMPLEMENTARY POLIPEPTIDEOS TO PEPTIDEOS OR PROTEINS HAVING A SEQUENCE OF AMINO ACIDS OR NUCLEOTIDE CODING SEQUENCE KNOWN AT LEAST PARTIALLY AND DESIGN METHODS OF THE SAME
WO2002044215A3 (en) Hybrid antibodies
CA2128511A1 (en) Monomeric and dimeric antibody-fragment fusion proteins
ATE172743T1 (en) DETECTION OF COLLAGEN DEGRADATION -I(IN VIVO)
DK0759944T3 (en) Enhancements to and related to peptide delivery
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
CA2111645A1 (en) Fibrinogen fragment e peptides and antibodies thereto
NO986088D0 (en) Polypeptides with the ability to form antigen binding structures with specificity
WO2001064877A3 (en) Human schizophrenia gene
ATE327328T1 (en) ADIPOCYTE-SPECIFIC PROTEIN HOMOLOGUE
WO1995011975A3 (en) Retroviral superantigens, superantigen peptides, and methods of use
ATE542138T1 (en) HER-2 BINDING ANTAGONISTS
WO1990006323A3 (en) Chimeric proteins incorporating a metal binding protein
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP1780219A3 (en) Protein S polypeptides and uses thereof
WO2001064876A3 (en) Human schizophrenia gene
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
CA2112701A1 (en) Proteins s polypeptides and uses thereof
WO2003033675A3 (en) Identification of binding partners for specific proteins
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
DK0889907T3 (en) Monoclonal antibodies that bind human growth hormone (hGH)
WO1998031796A8 (en) Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
GB2286189A (en) Recombinant specific binding protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814571.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 33432/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2355896

Country of ref document: CA

Ref document number: 2355896

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017007826

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 589139

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999969995

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017007826

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999969995

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 33432/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999969995

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017007826

Country of ref document: KR